Loading…
Edesa Biotech, Inc. is projected to rise to $8.94 by 2027, a +12% move from its current price of $7.97. EDSA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.18 | $7.97 | $8.85 | 0.00% |
| May 30 | $6.87 | $7.97 | $9.24 | 0.00% |
| May 31 | $6.65 | $7.97 | $9.55 | -0.01% |
| Jun 1 | $6.46 | $7.97 | $9.83 | -0.01% |
| Jun 2 | $6.31 | $7.97 | $10.07 | -0.01% |
| Jun 3 | $6.17 | $7.97 | $10.30 | -0.01% |
| Jun 4 | $6.04 | $7.97 | $10.51 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.04 | $7.97 | $10.51 | -0.01% |
| Week 2 | $5.39 | $7.97 | $11.79 | -0.03% |
| Week 3 | $4.93 | $7.97 | $12.87 | -0.04% |
| Week 4 | $4.58 | $7.97 | $13.86 | -0.05% |
| Week 5 | $4.29 | $7.96 | $14.79 | -0.07% |
| Week 6 | $4.04 | $7.96 | $15.69 | -0.08% |
| Week 7 | $3.83 | $7.96 | $16.57 | -0.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
EDSA is a healthcare stock trading with a current price of $7.97 and a market capitalization of $70.87M. It holds a rank of 4382 among peers. The stock sits in a price landscape shaped by a defined 30-day technical picture and a multi-year forecast that shows meaningful upside potential.
A major floor 90.0% below — a decisive break under it would weaken the trend.
The nearest floor, 35.5% below — buyers have tended to step in here.
The nearest ceiling, 129.4% above — a clean break opens room to run.
A major ceiling 196.2% above — clearing it would confirm fresh momentum.
Key EDSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.99 | Sell | $9.78 | Sell |
| MA 10 | $11.38 | Sell | $10.96 | Sell |
| MA 20 | $13.72 | Sell | $11.54 | Sell |
| MA 50 | $9.53 | Sell | $9.79 | Sell |
| MA 100 | $5.87 | Buy | $7.36 | Buy |
| MA 200 | $3.99 | Buy | $5.28 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.19 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -145.88 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.96 | Sell |
| ROC (12) | -51.10 | Sell |
| Bollinger %B (20,2) | 0.02 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 1.34 | Buy |
| Awesome (5,34) | -1.02 | Sell |
| Ultimate (7,14,28) | 32.67 | Neutral |
| Momentum (10) | -5.30 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 9.11 | Sell |
| ADX (14) | 21.46 | Sell |
| ATR (14) | 1.30 | Info |
Technically, the sentiment is BULLISH with an RSI14 of 40. The 50-day simple moving average is $9.53 and the 200-day simple moving average is $3.99. Support sits at $5.14 and resistance at $18.28, framing a 30-day price range of $4.00 to $15.89. These metrics frame near-term risk and potential for movement within the defined range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.80 | $7.97 | $10.52 | 0% | Neutral | |
| $6.44 | $8.94 | $13.45 | +12% | Neutral | |
| $8.01 | $11.81 | $18.88 | +48% | Bullish | |
| $8.78 | $13.62 | $22.83 | +71% | Bullish | |
| $10.79 | $17.54 | $30.58 | +120% | Bullish | |
| $10.32 | $17.53 | $31.62 | +120% | Bullish | |
| $8.05 | $14.27 | $26.53 | +79% | Bullish | |
| $9.13 | $16.85 | $32.18 | +111% | Bullish | |
| $10.27 | $19.72 | $38.60 | +147% | Bullish | |
| $13.03 | $26.00 | $52.07 | +226% | Bullish | |
| $12.84 | $28.53 | $62.76 | +258% | Bullish | |
| $28.28 | $62.85 | $144.57 | +689% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.80 | $7.97 | $9.43 | +0.00% |
| June 2026 | $6.74 | $8.08 | $10.04 | +1.36% |
| July 2026 | $6.52 | $7.96 | $10.14 | -1.51% |
| August 2026 | $5.83 | $7.20 | $9.36 | -9.45% |
| September 2026 | $5.71 | $7.13 | $9.41 | -0.97% |
| October 2026 | $6.15 | $7.77 | $10.40 | +8.91% |
| November 2026 | $6.14 | $7.83 | $10.60 | +0.73% |
| December 2026 | $5.97 | $7.68 | $10.52 | -1.91% |
Click any year to see its month-by-month EDSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDSA to range from $0.80 to $10.52 through 2026. The $7.97 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EDSA price prediction for 2027 points to an average of $8.94 (low $6.44, high $13.45) — a potential gain of +12% on today's $7.97. A consolidation phase looks the most probable path here.
In 2028, EDSA is projected to trade between $8.01 and $18.88, averaging $11.81 — a potential gain of +48% from today's $7.97. That is up +32% on the projected 2027 average. Momentum favours further upside here.
Edesa Biotech, Inc.'s 2029 outlook centres on $13.62, within a $8.78 to $22.83 range. That is up +15% on the projected 2028 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, EDSA could reach as high as $30.58, with a base case around $17.54 and support toward $10.79 — roughly +120% from $7.97. Momentum favours further upside here.
Expect EDSA to range from $10.32 to $31.62 through 2031. The $17.53 average target implies a +120% move from current prices. That is 0% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The EDSA price prediction for 2032 points to an average of $14.27 (low $8.05, high $26.53) — a potential gain of +79% on today's $7.97. Momentum favours further upside here.
In 2033, EDSA is projected to trade between $9.13 and $32.18, averaging $16.85 — a potential gain of +111% from today's $7.97. That is up +18% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Edesa Biotech, Inc.'s 2034 outlook centres on $19.72, within a $10.27 to $38.60 range. That is up +17% on the projected 2033 average. That marks a +147% change versus current levels. Momentum favours further upside here.
By 2035, EDSA could reach as high as $52.07, with a base case around $26.00 and support toward $13.03 — roughly +226% from $7.97. Buyers look set to stay in control over this stretch.
Expect EDSA to range from $12.84 to $62.76 through 2040. The $28.53 average target implies a +258% move from current prices. That is up +10% on the projected 2035 average. Momentum favours further upside here.
The EDSA price prediction for 2050 points to an average of $62.85 (low $28.28, high $144.57) — a potential gain of +689% on today's $7.97. Buyers look set to stay in control over this stretch.
Investing $1,000 in EDSA today (≈ 125.470514 EDSA) could be worth
$7,886.45
+$6,886.45 (+689%) by 2050 · US Dollar
Based on the average projected EDSA price of $62.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDSAwould be worth at today's price.
$1,000 invested in EDSA on May 27, 2025 (≈ 497.51244 EDSA) would be worth
$3,965.17
+$2,965.17 (+296.5%) today · 3.97× · US Dollar
Based on a EDSA entry price of $2.01 vs. today's $7.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.93 | $729.19 | -27.1% |
| 1 month ago | $11.17 | $713.52 | -28.6% |
| 3 months ago | $1.55 | $5,141.94 | +414.2% |
| 6 months ago | $1.75 | $4,554.29 | +355.4% |
| 1 year ago | $2.01 | $3,965.17 | +296.5% |
| All time (5.0y) ago | $41.72 | $191.04 | -80.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDSA forecast.
Our base-case forecast reaches $16.00 around 2030.
Implied market cap at $16.00: $142.27M
The multi-year forecast shows a bullish tilt across most years beyond 2026, with a neutral start in 2026 and 2027. The 2026 forecast lists a min of $0.80, an avg of $7.97, and a max of $10.52 (ROI 0%). By 2027, the avg is $8.94 with a 12.2% ROI and a max of $13.45.
The forecast accelerates thereafter, with 2028 avg $11.81 (48.2% ROI) and 2029 avg $13.62 (71% ROI). The path to 2030 shows an avg of $17.54 and a 120.1% ROI, with a max of $30.58. The 2031 forecast lines up with an avg of $17.53 and a 120% ROI, while 2032 carries an avg of $14.27 (79.1% ROI) and 2033 an avg of $16.85 (111.4% ROI).
By 2034 the avg rises to $19.72 (147.4% ROI) and 2035 to $26.00 (226.2% ROI). In the 2040 forecast the avg is $28.53 with a 258% ROI, and by 2050 the avg is $62.85 with a 688.6% ROI, and a max of $144.57. Sentiment shifts to BULLISH for most long-horizon years.
These figures are forecasts, not guarantees, and should be considered estimates with inherent uncertainty.
Tap a question to reveal the answer.
2030 avg price is $17.54, with a min of $10.79 and a max of $30.58; ROI 120.1%; sentiment BULLISH.
The forecast shows bullish sentiment in several years and a long-run uptrend to an avg of $62.85 by 2050 with a ROI of 688.6%. However, these are estimates and not guarantees.
Yes. The 2030 max is $30.58, 2031 max $31.62, 2033 max $32.18, 2040 max $62.76, and 2050 max $144.57, indicating potential to exceed $18 in multiple years.
The current price is $7.97.
Annualized volatility pct is 200.
Edesa Biotech, Inc. Community Discussion
0Share your Edesa Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.